Pretzel Therapeutics launches with $72.5m Series A to pioneer mitochondrial therapies

Pretzel set to leverage expertise in mitochondrial biology to advance novel treatments for both rare and common diseases and is backed by world-class investor syndicate.

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Pretzel set to leverage expertise in mitochondrial biology to advance novel treatments for both rare and common diseases and is backed by world-class investor syndicate.

Pretzel Therapeutics, a biotech seeking to harness the intricacies of mitochondrial biology to develop groundbreaking therapies, launched yesterday with a $72.5 million Series A financing to pioneer novel therapies to modulate mitochondrial function.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 2881

Pretzel Therapeutics

Longevity level(s):

  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.
  • Level 7: Targeted aging disease reversal
    Therapeutic interventions that stop or reverse age-related damage in specific organs (organ specific / tissue specific / localized reversal) or for age-related diseases including technologies like partial cellular reprogramming.

Overview

Pretzel Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class small-molecule and gene-editing therapeutics targeting mitochondrial dysfunction. The company's platform addresses dysregulated cellular bioenergetics through three modalities: genome correction, genome expression modulation, and mitochondrial quality control. Pretzel targets both rare genetic mitochondrial diseases and common age-related conditions including neurodegenerative disorders, metabolic diseases, and obesity, with the overarching mission of restoring cellular energy production and extending healthspan.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oyster surfaces with $60m and a tau degrader that travels light

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE